| Item Type | Name |
|
Academic Article
|
The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia.
|
|
Concept
|
Leukemia, Hairy Cell
|
|
Concept
|
Leukemia, B-Cell
|
|
Academic Article
|
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
|
|
Academic Article
|
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
|
|
Academic Article
|
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
|
|
Academic Article
|
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.
|
|
Academic Article
|
Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia.
|
|
Academic Article
|
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.
|
|
Academic Article
|
Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting.
|
|
Academic Article
|
Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells.
|
|
Academic Article
|
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
|
|
Academic Article
|
No cell is an island unto itself: the stromal microenvironment in chronic lymphocytic leukemia.
|
|
Academic Article
|
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
|
|
Academic Article
|
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
|
|
Academic Article
|
The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions.
|
|
Academic Article
|
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
|
|
Academic Article
|
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
|
|
Academic Article
|
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance.
|
|
Academic Article
|
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
|
|
Academic Article
|
Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.
|
|
Academic Article
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
|
|
Academic Article
|
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.
|
|
Academic Article
|
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
B cell receptor signaling in chronic lymphocytic leukemia.
|
|
Academic Article
|
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
|
|
Academic Article
|
The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.
|
|
Academic Article
|
Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
|
|
Academic Article
|
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
|
|
Academic Article
|
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
|
|
Academic Article
|
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
|
|
Academic Article
|
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.
|
|
Academic Article
|
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.
|
|
Academic Article
|
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.
|
|
Academic Article
|
Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.
|
|
Academic Article
|
Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..
|
|
Academic Article
|
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
|
|
Academic Article
|
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
|
|
Academic Article
|
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
|
|
Academic Article
|
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
|
|
Academic Article
|
Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
|
|
Academic Article
|
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
|
|
Academic Article
|
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.
|
|
Academic Article
|
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
|
|
Academic Article
|
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
|
|
Academic Article
|
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.
|
|
Academic Article
|
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
|
|
Academic Article
|
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
|
|
Academic Article
|
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
|
|
Academic Article
|
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
|
|
Academic Article
|
A phase 2 study of idelalisib plus rituximab in treatment-na?ve older patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
The importance of the tissue microenvironment in hairy cell leukemia.
|
|
Academic Article
|
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
|
|
Academic Article
|
Three Newly Approved Drugs for Chronic Lymphocytic Leukemia
|
|
Academic Article
|
Targeting CXCR4 in chronic lymphocytic leukemia
|
|
Academic Article
|
PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL)
|
|
Academic Article
|
Cell trafficking in chronic lymphocytic leukemia
|
|
Academic Article
|
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies
|
|
Academic Article
|
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy
|
|
Academic Article
|
Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome
|
|
Academic Article
|
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia
|
|
Academic Article
|
The microenvironment in chronic lymphocytic leukemia
|
|
Academic Article
|
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
|
|
Academic Article
|
Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia
|
|
Academic Article
|
The importance of the tissue microenvironment in hairy cell leukemia
|
|
Academic Article
|
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia
|
|
Academic Article
|
Chronic lymphocytic leukemia therapy
|
|
Academic Article
|
β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia
|
|
Academic Article
|
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
|
|
Academic Article
|
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
|
|
Academic Article
|
BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
|
|
Academic Article
|
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia
|
|
Academic Article
|
CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates
|
|
Academic Article
|
Nurse-like cells that support survival of chronic lymphocytic leukemia cells are derived from blood monocytes
|
|
Academic Article
|
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
|
|
Academic Article
|
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
|
|
Academic Article
|
Cell Trafficking in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
|
|
Academic Article
|
CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates.
|
|
Academic Article
|
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
|
|
Academic Article
|
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.
|
|
Academic Article
|
?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib for Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
|
|
Academic Article
|
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
|
|
Academic Article
|
Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
|
|
Academic Article
|
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
|
|
Academic Article
|
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
|
|
Academic Article
|
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
|
|
Academic Article
|
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
|
|
Academic Article
|
Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
|
|
Academic Article
|
Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.
|
|
Academic Article
|
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
|
|
Academic Article
|
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.
|
|
Academic Article
|
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
|
|
Academic Article
|
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
|
|
Academic Article
|
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
|
|
Academic Article
|
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.
|
|
Academic Article
|
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
|
|
Academic Article
|
Single-agent ibrutinib in treatment-na?ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
|
|
Academic Article
|
Erratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).
|
|
Academic Article
|
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
|
|
Academic Article
|
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
|
|
Academic Article
|
Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
|
|
Academic Article
|
Safety Analysis of Four Randomized Controlled?Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
|
|
Academic Article
|
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-na?ve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
|
|
Academic Article
|
STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
|
|
Academic Article
|
Duvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
|
|
Academic Article
|
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
|
|
Academic Article
|
Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases.
|
|
Academic Article
|
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
|
|
Academic Article
|
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
|
|
Academic Article
|
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
|
|
Academic Article
|
Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.
|
|
Concept
|
Pre-B-Cell Leukemia Transcription Factor 1
|
|
Concept
|
Myeloid Cell Leukemia Sequence 1 Protein
|
|
Academic Article
|
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
|
|
Academic Article
|
Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia.
|
|
Academic Article
|
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
|
|
Academic Article
|
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
|
|
Academic Article
|
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
|
|
Academic Article
|
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
|
|
Academic Article
|
STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.
|
|
Academic Article
|
Bruton Tyrosine Kinase Inhibitors: Present and Future.
|
|
Academic Article
|
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
|
|
Academic Article
|
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
|
|
Academic Article
|
Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
|
|
Academic Article
|
Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts.
|
|
Academic Article
|
Treatment of Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
|
|
Academic Article
|
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
|
|
Academic Article
|
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
|
Academic Article
|
Integrating New Therapies for Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.
|
|
Academic Article
|
B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia.
|
|
Academic Article
|
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
|
|
Academic Article
|
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.
|
|
Academic Article
|
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
|
|
Academic Article
|
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
|
|
Academic Article
|
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for =5 Years in the RESONATE-2 Study.
|
|
Academic Article
|
Molecular map of chronic lymphocytic leukemia and its impact on outcome.
|
|
Academic Article
|
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8?Years: A Plain Language Summary.
|
|
Academic Article
|
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
|
|
Academic Article
|
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
|
|
Academic Article
|
Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report.
|
|
Academic Article
|
Chronic Lymphocytic Leukemia: Disease Biology.
|
|
Academic Article
|
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
|